As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT ...

Has biote Corp. (BTMD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. biote Corp. is one of 1021 companies in the Medical group.

“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements ...

One company value investors might notice is biote Corp. (BTMD). BTMD is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 12.10.

“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements business ...